This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Tuesday's Early Winners & Losers

Shares of Sanmina-SCI (SANM - Get Report) sank in late trading Monday after the electronics-manufacturing services company lowered its third-quarter estimates.

The company expects earnings for the recently ended quarter to be 6 cents to 7 cents a share, before items. Its previous forecast called for earnings of 8 cents to 10 cents a share. Sanmina estimates that third-quarter revenue totaled $2.71 billion, at the bottom of its guidance of $2.7 billion to $2.8 billion. Analysts polled by Thomson First Call had an average estimate for earnings of 9 cents a share on $2.75 billion in revenue. The company attributed the shortfall to a less-favorable product mix, lower-than-expected profitability in its computing business, and slower-than-anticipated improvement in its enclosure business. Shares tumbled 65 cents, or 15%, to $3.62 in after-hours trading.

Neurocrine Biosciences (NBIX) posted a wider second-quarter loss that missed analysts' estimates, sending its shares lower after hours. The company recorded a loss of $27.4 million, or 73 cents a share, compared with a loss of $5.6 million, or 15 cents a share, a year earlier. Revenue dropped to $9.2 million from $33.2 million a year earlier. Wall Street anticipated a loss of 72 cents a share and revenue of $22.9 million. Neurocrine attributed the drop in revenue to lower revenue recognized under collaborative agreements.

Neurocrine also reiterated that it will need to conduct more clinical trials for the insomnia drug Indiplon, and that it might need more tests for the immediate-release version. In May, the Food and Drug Administration delayed approving an immediate-release version of Indiplon and rejected a long-acting version of the drug. Neurocrine on Monday said it now expects a loss of more than $130 million for 2006, with a net cash burn of $100 million. Shares fell 33 cents, or 3.5%, to $9.09 in late trading.

Shares of Pharmaceutical Product Development (PPDI) advanced after the contract-research company posted second-quarter results that beat Wall Street's expectations. The company posted a profit of $36.4 million, or 31 cents a share, up from $20.8 million, or 18 cents a share a year ago. Revenue climbed 26% to $309 million. Analysts on average projected earnings of 29 cents a share and revenue of $274.5 million in revenue. After hours, shares rose $2.31, or 6.4%, to $38.27.
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AVSR $0.00 40.00%
ACTS $1.61 0.63%
DGII $10.63 0.76%
NBIX $42.75 -0.37%
SNE $23.93 0.34%


Chart of I:DJI
DOW 17,641.16 -10.10 -0.06%
S&P 500 2,046.67 -4.45 -0.22%
NASDAQ 4,712.4240 -13.2150 -0.28%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs